Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Buy
Sell